MBC

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics

Retrieved on: 
水曜日, 12月 13, 2023
Genetics, Research, SAN, Therapy, Gene, Toxicity, IND, Biotechnology, FSHD, AVM, Patient, Mission, Idiopathic pulmonary fibrosis, Doctor of Philosophy, Altai, Drug resistance, TSE, Genome, Chromatin, Factorization of polynomials, Drug discovery, Cancer, TippingPoint, MBC, San Francisco Bay Area, Facioscapulohumeral muscular dystrophy, Pharmaceutical industry, Astellas Pharma

"We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.

Key Points: 
  • "We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.
  • "It's such an honor to be a recipient of the Astellas Future Innovator Prize, which will further support TippingPoint's research," said Laura Hsieh, CEO of TippingPoint Biosciences.
  • "Astellas' deep industry expertise coupled with MBC BioLabs' resources will play integral roles in accelerating our drug discovery development and successfully implementing TippingPoint's programs.
  • Both TippingPoint Biosciences and Altay Therapeutics will reside at MBC BioLabs with the next year sponsored by Astellas.

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Retrieved on: 
金曜日, 12月 8, 2023
Trastuzumab, Research, Progression-free survival, RECIST, Fulvestrant, Breast cancer, Jazz Pharmaceuticals, Patient, PFS, Part, Corr, DOR, MBC, DCR, Pertuzumab, HER2, Cancer, Vall d'Hebron University Hospital, BS 5839 Part 1, Metastasis, HR, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • Patients treated with the combination regimen received a median of four prior systemic regimens in the metastatic setting (range, 1-12).
  • Recommended doses of the zanidatamab plus palbociclib and fulvestrant combination therapy were determined in Part 1 of the study.
  • Patients treated with the combination regimen achieved a cORR of 35% and DCR of 91%.

Montclair Breast Center Celebrates a Trailblazer: Breast Surgeon Elissa J. Santoro, MD

Retrieved on: 
火曜日, 12月 5, 2023
Woman, Highlawn, West Virginia, Breast cancer, Breast Cancer Research, Karger Publishers, Surgeon, Hospital, Patient, Research, FACS, Health, Friends, Mentorship, Breast, MD, Hand, St. Vincent's Hospital, MBC, Genesis Health System, Elective surgery, Female, Publication, Environment, Health department, Birth control, Medicine

Dr. Santoro is a distinguished and revolutionary breast surgeon whose contributions have left an indelible mark on the field of breast health.

Key Points: 
  • Dr. Santoro is a distinguished and revolutionary breast surgeon whose contributions have left an indelible mark on the field of breast health.
  • She founded the Breast Care and Treatment Center in Livingston, NJ and has appeared on several televised educational programs.
  • Her leadership at Montclair Breast Center fosters an environment of innovation where cutting-edge research and patient-centric care go hand in hand.
  • Coming full circle, Dr. Santoro joined Dr. Elliott at Montclair Breast Center in March 2022.

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings

Retrieved on: 
木曜日, 11月 30, 2023
Bone marrow, Trae Elston, Research, Safety, ASH, NACLC, Fulvestrant, Acute leukemia, International Association, MD Anderson Cancer Center, LBL, Breast cancer, ESMO, Jazz Pharmaceuticals, Patient, ASCO, MBC, Acute lymphoblastic leukemia, Conference, NSAA, Abstract, HER2, Lung cancer, Jazz, Society, ALL, HR, Pharmaceutical industry

DUBLIN, Nov. 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9; 11 abstracts at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12; and two abstracts at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC) from December 1-3. New data include updated findings from a Phase 2a trial of the investigational HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free option for HER2+/ HR+ metastatic breast cancer (mBC).

Key Points: 
  • New data include updated findings from a Phase 2a trial of the investigational HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free option for HER2+/ HR+ metastatic breast cancer (mBC).
  • "SABCS will also feature data from a trial of zanidatamab in neoadjuvant breast cancer.
  • An investigator-sponsored (MD Anderson Cancer Center) SABCS poster presentation featuring results of a Phase 1 trial evaluating neoadjuvant zanidatamab in patients with stage 1 node-negative HER2+ breast cancer as a single-agent chemotherapy-free option.
  • Treatment‐related adverse events (TRAEs) ≥ grade 3 occurred in 126/228 (55%) patients with no TRAEs that led to death.1
    The Jazz and partner-supported presentations at SABCS 2023 are:

Dr. Jessica Clague DeHart of Claremont Graduate University and LYTE Foundation to receive data and findings of the important Health of Women (HOW) Study® and the Metastatic Breast Cancer Collateral Damage (MBCCD) Project

Retrieved on: 
水曜日, 11月 29, 2023
Diet, Woman, Associate, Research, Breast cancer, Breast Cancer Research, HOW, Exercise, Disease, LOS, Collateral damage, Claremont Graduate University, MBC, Quality of life, Molecular Cancer Research, Birth control

LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The 6-year Health of Women (HOW) Study was a first-of-its kind international online study to better understand breast cancer and its underlying cause. The HOW Study® asked health-related questions on topics like family history, reproductive health, diet, and exercise. Over the course of the study, more than 65,000 women participated to help identify how family history, reproductive health, diet and exercise contribute to the cause of breast cancer. Preliminary results from the HOW Study revealed a critical need to address issues often overlooked among those living with metastatic breast cancer (MBC). While industry partners develop treatments that will keep people alive longer, the MBCCD project set out to help them live better. This project documented a full range of collateral damage experienced by those living with MBC and is currently developing a set of recommendations aimed at improving quality of life.

Key Points: 
  • Dr. Susan Love Foundation to transfer data and findings to continue the work on breast cancer research and other women's health issues.
  • Over the course of the study, more than 65,000 women participated to help identify how family history, reproductive health, diet and exercise contribute to the cause of breast cancer.
  • Preliminary results from the HOW Study revealed a critical need to address issues often overlooked among those living with metastatic breast cancer (MBC).
  • Dr. Jessica Clague DeHart is a molecular cancer epidemiologist, Associate Professor at Claremont Graduate University, and the CEO/Founder of LYTE Foundation.

EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update

Retrieved on: 
木曜日, 12月 14, 2023
Growth, Bridge, Drug discovery, Evotec, EVO, Novo Nordisk, Mass General Brigham, Biomarker, ISIN, Research, Frankfurt Stock Exchange, MDAX, Creative Biolabs, Yale University, Harvard University, EBITDA, MBC, Match point, LabCentral, Pharmaceutical industry, Arms industry, Fine chemical, Silviculture

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.
  • Costs of € 43.9 m were incurred in 2023 as a direct result of the cyber-incident in early April, including additional external expenditures and internal recovery contributions.
  • In response to the criminal cyber-attack, Evotec took immediate action to contain and remediate the attack by taking its external-facing systems offline.
  • This was deemed necessary to protect all the Company’s partners and stakeholders and meant Evotec could ensure that the integrity of scientific data remained unaffected.

MasterBrand Reports Third Quarter 2023 Financial Results

Retrieved on: 
火曜日, 11月 7, 2023
Manufacturing, Interior Design, Other Manufacturing, Residential Building & Real Estate, Construction & Property, Insurance, NYSE, Tax, Public expenditure, EBITDA, Security, GAAP, Growth, Fortune Brands Home & Security, Webcast, Depreciation, Culture, Forecasting, Investment, MBC, Video game, Management, Security (finance), Bank, Bookkeeping

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced third quarter 2023 financial results.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced third quarter 2023 financial results.
  • “Given our financial performance in the third quarter and continued operational excellence, we are raising our adjusted EBITDA1 and related margin outlook for the full year 2023,” said Andi Simon, Executive Vice President and Chief Financial Officer.
  • ET today, November 7, 2023, to discuss the financial results and business outlook.
  • Non-GAAP financial measures should be considered in addition to, not as a substitute for, other financial measures prepared in accordance with GAAP.

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
火曜日, 11月 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Abdominal pain, Constipation, SOC, Headache, Food, Progression-free survival, European Commission, Vomiting, Diarrhea, Prevalence, PFS, Safety, DSM-IV codes, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV disease progression rates, Holding, Nausea, Multimedia, Civil service commission, ESR1, Risk, Triglyceride, MBC, ER, Breast cancer, Anemia, Woman, Indigestion, Cancer, Therapy, Arthralgia, Patient, Creatinine, Potassium, Death, Back pain, Cholesterol, Fatigue, Pharmaceutical industry

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialize ORSERDU upon its regulatory approval in China.
  • “Patients living with metastatic breast cancer need effective and tolerable options,” said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
火曜日, 11月 7, 2023
Neoplasm, Patient, Abdominal pain, Constipation, SOC, Headache, Food, Progression-free survival, Fatigue, European Commission, Vomiting, Diarrhea, PFS, Safety, DSM-IV codes, HIV disease progression rates, Holding, Nausea, Republic, Civil service commission, ESR1, Risk, Triglyceride, MBC, ER, Breast cancer, Anemia, Woman, Oncology, Indigestion, Cancer, Therapy, Arthralgia, Creatinine, Potassium, Death, Back pain, Cholesterol, Mutation, Menarini, Medical imaging, Pharmaceutical industry

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialise ORSERDU upon its regulatory approval in China.
  • "Patients living with metastatic breast cancer need effective and tolerable options," said Elcin Barker Ergun, CEO of the Menarini Group.
  • "We are proud to partner with SciClone in an effort to register a new breast cancer treatment for patients in China that can offer efficacy in a once-daily pill."

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
火曜日, 11月 7, 2023
Neoplasm, Patient, Abdominal pain, Constipation, SOC, Headache, Food, Progression-free survival, Fatigue, European Commission, Vomiting, Diarrhea, PFS, Safety, DSM-IV codes, HIV disease progression rates, Holding, Nausea, Republic, Civil service commission, ESR1, Risk, Triglyceride, MBC, ER, Breast cancer, Anemia, Woman, Oncology, Indigestion, Cancer, Therapy, Arthralgia, Creatinine, Potassium, Death, Back pain, Cholesterol, Mutation, Menarini, Medical imaging, Pharmaceutical industry

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialise ORSERDU upon its regulatory approval in China.
  • "Patients living with metastatic breast cancer need effective and tolerable options," said Elcin Barker Ergun, CEO of the Menarini Group.
  • "We are proud to partner with SciClone in an effort to register a new breast cancer treatment for patients in China that can offer efficacy in a once-daily pill."